graph Evidence gap map comparisons
ipilimumab based treatmentatezolizumab based treatmentdurvalumab based treatmentnivolumab based treatmentpembrolizumab based treatmentdurvalumab plus tremelimumabImmune checkpoint association
ipilimumab plus SoC atezolizumab plus SoC durvalumab plus etoposide and platin nivolumab alone pembrolizumab plus SoC durvalumab plus tremelimumab plus SoC nivolumab plus ipilimumab
Extensive stage SCLC (Es-SCLC) - maintenance (M) 2     
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) 5           
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
Comparator:  vs placebo;   vs placebo plus SoC;   vs etoposide plus platin; 
Risk of bias:  low;   some concerns;   high;  NA;